Cyclerion Therapeutics, Inc.
CYCN
$2.53
$0.062.43%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -69.03% | -92.31% | -- |
| Gross Profit | -- | -- | 69.03% | 92.31% | -- |
| SG&A Expenses | -36.68% | -41.76% | -16.19% | -41.77% | -46.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.35% | -51.24% | -25.79% | -50.60% | -59.71% |
| Operating Income | 127.97% | 58.39% | 25.79% | 50.60% | 59.71% |
| Income Before Tax | 131.29% | 87.76% | 26.68% | 51.62% | 60.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 131.29% | 87.76% | 26.68% | 51.62% | 60.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 100.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 131.29% | -109.56% | 68.38% | 77.83% | 76.52% |
| EBIT | 127.97% | 58.39% | 25.79% | 50.60% | 59.71% |
| EBITDA | -- | -- | -- | -- | 60.07% |
| EPS Basic | 129.84% | -109.21% | 71.25% | 80.65% | 78.96% |
| Normalized Basic EPS | 131.14% | 73.23% | 33.33% | 57.79% | 66.35% |
| EPS Diluted | 129.84% | -109.33% | 71.07% | 80.65% | 78.96% |
| Normalized Diluted EPS | 131.14% | 73.23% | 33.33% | 57.79% | 66.35% |
| Average Basic Shares Outstanding | 8.73% | 3.74% | 9.99% | 14.61% | 7.59% |
| Average Diluted Shares Outstanding | 8.73% | 3.74% | 9.99% | 14.61% | 7.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
